Company Overview
AbCellera Biologics Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where it engages in the discovery and development of antibody-based medicines designed for indications with unmet medical needs in the United States. The company's portfolio includes lead products such as ABCL635, a non-hormonal medicine currently in Phase 2 clinical trials to treat moderate-to-severe vasomotor symptoms, alongside ABCL575 which supports its therapeutic development pipeline. As of the latest available data, the company holds a market capitalization of $1.00B, generates annual revenue of $75.13M, and employs a workforce of 562 individuals across its operations. These valuation and revenue figures indicate that AbCellera Biologics Inc. is a mid-sized entity within the biotechnology landscape, possessing a substantial cash reserve relative to its market cap but operating without profitability at the current stage of development. The combination of a $1.00B market cap and $75.13M in revenue suggests the market values the company's pipeline potential significantly, even though the current financial scale reflects the typical capital-intensive nature of a clinical-stage biotechnology firm.
Financial Health
The company reported revenue of $75.13M for the trailing twelve months, yet it recorded a net income of -$146,412,000 and an EBITDA of -$194,932,000, revealing a significant gap where operating expenses vastly exceed revenue generation. This disparity highlights a cost structure characteristic of early-stage biotechnology development, where research, clinical trial costs, and personnel expenses are heavily weighted against current sales. The firm generated free cash flow of -$175,997,376, indicating that its current financial flexibility relies entirely on existing cash reserves rather than operational cash generation. Despite the negative operating cash flow, the company maintains a cash balance of $533.83M against total debt of $143.22M, resulting in a debt-to-equity ratio of 14.81 which points to a highly leveraged balance sheet relative to its equity base. However, the current ratio stands at 11.32, suggesting that the company possesses an extremely strong position regarding short-term liquidity and its ability to cover immediate obligations with current assets. The gross margin is listed at -148.7%, the operating margin is -63.7%, and the profit margin is -194.9%, all of which are negative indicators reflecting the substantial costs of drug development prior to commercialization. Return on Equity is -14.5% and Return on Assets is -10.0%, metrics that reveal management is currently utilizing shareholder capital and assets to fund growth initiatives rather than generating returns, a standard dynamic for companies in the clinical trial phase.
Valuation Assessment
The company exhibits a P/E Ratio (TTM) of N/A due to its lack of earnings, while the forward P/E is reported as -4.30, implying that future earnings projections are either negative or insufficient to support a traditional multiple. The price-to-book ratio is 1.03, indicating that the market values the company at a slight premium over its book value, which often occurs when investors anticipate future value creation from the pipeline. Alternative valuation metrics show a price-to-sales ratio of 13.36 and an EV/EBITDA of -3.14, suggesting that the market is pricing the stock based on revenue potential and asset backing rather than current profitability or earnings power. The 52-week high for the stock is $6.51 and the 52-week low is $1.89, placing the current trading range within a wide band that reflects high volatility typical of small-cap biotechnology firms. The beta value is 0.87, which indicates that the stock's price volatility is slightly lower than the broader market, though it still moves in tandem with general market fluctuations. These valuation figures collectively present a picture of a high-risk, high-reward asset where the market is willing to pay a multiple of revenue despite the absence of positive earnings.
Growth & Income
Revenue growth for the company is an impressive 788.2% year-over-year, whereas earnings growth is N/A, indicating that while top-line sales are expanding rapidly, the bottom line remains negative and earnings are not yet growing at a pace that can be quantified due to losses. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available earnings and cash flows back into research, development, and clinical operations rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms in the development phase, prioritizing the advancement of lead products like ABCL635 over immediate shareholder returns. The overall growth and income profile is defined by explosive revenue expansion coupled with significant cash burn, resulting in a financial structure that relies on capital markets or internal cash reserves to sustain operations until commercialization milestones are reached.